Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity

doi:10.3748/wjg.v21.i37.10688

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 37

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9227)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

1694

WORD

261

HTML

4310

Figures (1-2)

217

Tables (1-6)

205

Sum=6687

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1137

Download

1403

Sum=2540

Oct 7, 2015 (publication date) through Dec 21, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Oct 7, 2015; 21(37): 10688-10696
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10688

Open in New Tab Full Size Figure Download Figure

Figure 1 Disease-free survival (A), overall survival (B), and local control (C). DFS: Disease-free survival; OS: Overall survival; LC: Local control.

Open in New Tab Full Size Figure Download Figure

Figure 2 Colostomy-free survival. A: Colostomy-free survival (CFS) all disease stages; B: CFS stage I-II vs IIIA-IIIB.

Citation: Belgioia L, Vagge S, Agnese D, Garelli S, Murialdo R, Fornarini G, Chiara S, Gallo F, Bacigalupo A, Corvò R. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. World J Gastroenterol 2015; 21(37): 10688-10696
URL: https://www.wjgnet.com/1007-9327/full/v21/i37/10688.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i37.10688